References
  1. Bernatsky S, Clarke AE, ZahediNiaki O et al (2017) Malignancy in pediatric-onset systemic lupus erythematosus. J Rheumatol 44(10): 1484-1486. doi: 10.3899/jrheum.170179.
  2. Ladouceur A, Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S (2020) Cancer and systemic lupus erythematosus. Rheum Dis Clin North 46: 533-550. doi: 10.1016/j.rdc.2020.05.005.
  3. Song L, Wang Y, Zhang J, Song N, Xu X, Lu Y (2018) The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta- analysis. Arthritis Res Ther 20: 270. doi:10.1186/s13075-018-1760-3.
  4. Lispemeyer EA (1972) Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression. Arthritis Rheum 15: 183-186. doi:10.1002/art.1780150207.
  5. Kaulen LD, KarschniaP, Dietrich J, Baehring JM (2020) Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. Journal of Neurooncolgy149: (1): 153-159. Doi: 10.1007/s11060-20-03583-9.
  6. Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundstrom C, Amini RM, Hagberg H (2017) Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. Acta Oncol 56(4): 599-607. Doi: 10.1080/0284186X.2016.1270465.
  7. Ichikawa T, Shimojima Y, Kishida D, Kaneko T, Sekijima Y (2021) Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus : case-based review. Rheumatol Int 41(5):1009-1017. Doi: 10.1007/s00296-020-04569-6.
  8. Bernatsky S, Ramsey-Goldman R, et al. Lymphoma risk in systemic lupus:effects of disease activity versus treatment. Ann Rheum Dis 2014; 73: 138-142. Doi:10.1136/annrheumdis-2012-202099.
  9. Drabourg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013; 535738. Doi: 10.1155/2013/535738.